# A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

> **NCT07713290** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Gene Key Life Technology Co., Ltd** · enrollment: 6 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Unresectable Hepatocellular Cancer

## Interventions

- **DRUG:** GKL-006 Injection
- **PROCEDURE:** Transarterial chemoembolization (TACE)

## Key facts

- **NCT ID:** NCT07713290
- **Lead sponsor:** Beijing Gene Key Life Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2026-11-12
- **Final completion:** 2027-02-28
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713290, "A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07713290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*